Verve Therapeutics Expands Board with Two New Members

Verve Therapeutics (VERV) has provided an announcement.

Verve Therapeutics, Inc. has expanded its Board of Directors to nine and welcomed Jodie Morrison and Ourania “Nia” Tatsis, Ph.D., as new members. Morrison, now on the Compensation Committee, and Tatsis, a Vertex Pharmaceuticals executive, are appointed as independent Class I and Class III directors, respectively. Both will receive the same compensation as other non-employee directors, including an option to purchase company shares. Their roles are solidified by standard indemnification agreements, ensuring protection against certain legal expenses related to their directorship duties.

See more data about VERV stock on TipRanks’ Stock Analysis page.